Evidence map›Paper›PMID 25420283›Full record

SynthesisHaematologica2014

Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.

David Rampton, Joergen Folkersen, Steven Fishbane, Michael Hedenus, Stefanie Howaldt, Francesco Locatelli, Shalini Patni, Janos Szebeni, Guenter Weiss

2 registry-linked trialsOpen access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 123 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 5 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05292001 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

Role of Single-dose Intravenous Iron Therapy for the Treatment of Anemia in the Setting of Orthopaedic Trauma: a Pilot Study

TypeinterventionalSponsorOregon Health and Science UniversityRan2022 to 2026Enrolled150ConditionsAcute Blood Loss Anemia, FractureArmsIron-Dextran Complex Injection [InFed], Saline Placebo
NCT05590260 phase3completednot on this mapstarted 2023, after this paper: background citation

Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research

TypeinterventionalSponsorNICHD Global Network for Women's and Children's HealthRan2023 to 2025Enrolled4,857ConditionsPostpartum AnemiaArmsFerric carboxymaltose (FCM) and folic acid tablets, Oral iron tablets and folic acid tablets
3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 307 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Article
  17. Article
  18. Intravenous iron reactions: Insights from an allergy and immunology perspective.The journal of allergy and clinical immunology. Global · 2025
    Article
  19. Article
  20. Observational

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 7 countries.

David RamptonBarts and the London School of Medicine and Dentistry, London, UK d.rampton@qmul.ac.uk.
Joergen FolkersenMedbusiness, Farum, Denmark.
Steven FishbaneHofstra North Shore-LIJ School of Medicine, New York, NY, USA.
Michael HedenusDept of Haematology, Sundsvalls Hospital, Sundsvall, Sweden.
Stefanie HowaldtResearch Institute for IBD, HaFCED GmbH&Co. KG, Hamburg, Germany.
Francesco LocatelliAlessandro Manzoni Hospital, Lecco, Italy.
Shalini PatniBirmingham Heartlands Hospital, UK.
Janos SzebeniNanomedicine Research and Education Center, Semmelweis University, Budapest, Hungary.
Guenter WeissDepartment for Internal Medicine VI, Medical University of Innsbruck, Austria.
Alessandro Manzoni Hospital · ITForschungsinstitut für Logistik · DEHeartlands Hospital · GBHofstra University · USInnsbruck Medical University · ATQueen Mary University of London · GBSemmelweis University · HUSundsvall Municipality · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper reviews their frequency, pathogenesis and risk factors, and provides recommendations about their management and prevention. Complement activation-related pseudo-allergy triggered by iron nanoparticles is probably a more frequent pathogenetic mechanism in acute reactions to current formulations of intravenous iron than is an immunological IgE-mediated response. Major risk factors for hypersensitivity reactions include a previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy, and possibly systemic inflammatory diseases. Early pregnancy is a contraindication to iron infusions, while old age and serious co-morbidity may worsen the impact of acute reactions if they occur. Management of iron infusions requires meticulous observation, and, in the event of an adverse reaction, prompt recognition and severity-related interventions by well-trained medical and nursing staff.

Indexed as

Administration, IntravenousAnemia, Iron-DeficiencyDisease ManagementDrug HypersensitivityHumansIncidenceIronRisk FactorsIron

Identifiers

PMID25420283
PMCPMC4222472
OpenAlexW2056969309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.